Jifeng Feng
A5100728900- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer-related molecular mechanisms research
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Advanced Breast Cancer Therapies
- MicroRNA in disease regulation
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Circular RNAs in diseases
- Genetic factors in colorectal cancer
- Cancer-related gene regulation
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Epigenetics and DNA Methylation
- Neutropenia and Cancer Infections
Guangxi Maternal and Child Health Hospital
2008-2025
Jiangsu Cancer Hospital
2015-2024
Nanjing Medical University
2015-2024
Zhejiang Cancer Hospital
2015-2024
Chinese Academy of Sciences
2023-2024
Cancer Hospital of Chinese Academy of Medical Sciences
2023
University of Chinese Academy of Sciences
2023
Second Affiliated Hospital of Nanjing Medical University
2020
Second Military Medical University
2013-2019
Xuzhou Medical College
2016-2017
Purpose In Asian countries, paclitaxel once per week is used as second-line treatment in advanced gastric cancer, including human epidermal growth factor receptor 2 (HER2) –positive tumors. The role of anti-HER2 agents, lapatinib, this setting and population unclear. Patients Methods TyTAN was a two-part, parallel-group, phase III study patients. An open-label, dose-optimization (n = 12) followed by randomized 261), which patients who were HER2 positive fluorescence situ hybridization (FISH)...
Purpose The phase III BEYOND trial was undertaken to confirm in a Chinese patient population the efficacy seen with first-line bevacizumab plus platinum doublet chemotherapy globally conducted studies. Patients and Methods age ≥ 18 years locally advanced, metastatic, or recurrent advanced nonsquamous non–small-cell lung cancer (NSCLC) were randomly assigned receive carboplatin (area under curve, 6) intravenously paclitaxel (175 mg/m 2 ) (CP) on day 1 of each 3-week cycle, for ≤ six cycles,...
IntroductionSintilimab, an anti–programmed death 1 antibody, plus pemetrexed and platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We conducted randomized, double-blind, 3 study to compare the safety of sintilimab with placebo, both combination such chemotherapy (ClinicalTrials.gov: NCT03607539).MethodsA total 397 patients previously untreated, locally advanced or metastatic without sensitizing EGFR anaplastic lymphoma kinase genomic aberration were...
Apatinib is an oral, highly potent tyrosine-kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750 mg/day with substantial antitumor activity. This phase II aims to evaluate optimum level for efficacy and safety apatinib monotherapy in heavily pretreated patients metastatic triple negative breast cancer (mTNBC) China. IIa was first performed among 25 previously treated anthracycline and/or taxane. All received p.o. a 4-week cycle. Subsequently, IIb 59 activated,...
As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal carcinoma (NPC). This study was aimed evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) for recurrent or metastatic NPC (RM-NPC) refractory standard chemotherapy.In this single-arm, multicenter phase II study, patients with RM-NPC received 3 mg/kg toripalimab once every 2 weeks via intravenous infusion until confirmed disease progression unacceptable toxicity. The...
Exosomes derived from lung cancer cells confer cisplatin (DDP) resistance to other cells. However, the underlying mechanism is still unknown. A549 DDP (A549/DDP) was established. Microarray used analyze microRNA (miRNA) expression profiles of cells, A549/DDP exosomes, and exosomes. There a strong correlation miRNA between exosomes their maternal A total 11 miRNAs were significantly upregulated both in compared with contrast 31 downregulated also observed. miR-100-5p most prominent decreased...
Exosomes are small extracellular membrane vesicles of endocytic origin released by many cells that could be found in most body fluids. The main functions exosomes cellular communication and waste clean-up. This study was conducted to determine the involvement regulation sensitivity lung cancer cell line A549 cisplatin (DDP). When DDP added cells, secretion strengthened. Addition secreted other increased resistance these DDP. Upon exposure DDP, expression levels several miRNAs mRNAs...
Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as first-line treatment for locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC; ClinicalTrials.gov identifier: NCT03849768).Patients at 53 sites China were randomly assigned 1:1 to receive either (110 mg)...
Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation EGFR tyrosine kinase inhibitor (TKI) with revealed activity against EGFR-sensitizing mutations and T790M mutation.Patients locally advanced or metastatic NSCLC who developed an mutation after progression on first- second-generation TKI therapy were enrolled in this registrational phase 2 trial of aumolertinib at 110 mg orally once daily (NCT02981108). The primary end point was objective response rate (ORR) by...
Although observational studies have reported associations between serum C-reactive protein (CRP) concentration and risks of lung, breast, colorectal cancer, inconsistent or absent evidences were showed for other cancers. We conducted a pan-cancer analysis to comprehensively assess the role CRP, including linearity non-linearity associations.We analyzed 420,964 cancer-free participants from UK Biobank cohort. Multivariable-adjusted Cox proportional hazards model was evaluate observed...
Importance For patients with non–small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited. Objective To compare the efficacy of ivonescimab plus chemotherapy alone for relapsed advanced or metastatic epidermal growth factor receptor ( ) variant. Design, Setting, and Participants Double-blind, placebo-controlled, randomized, phase 3 trial at 55 sites in China...